A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AEON SEC filings page.
This page shows AEON Biopharma, Inc. (AEON) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AEON remains a development-stage business: shrinking R&D accompanies smaller losses, but liabilities exceed assets and financing supplies cash.
Operating cash outflow narrowed from$35.6M in FY2022 to$17.3M in FY2025. R&D also fell88.2% across that span, so lower cash use appears tied to a smaller development program, not demonstrated commercial cash generation. In FY2025, financing cash inflows of$20.3M exceeded the operating cash outflow of$17.3M , showing that external funding remained central to the cash pattern.
FY2025 liabilities of
R&D fell
Financial Health Signals
We do not publish a peer-relative financial health score for AEON Biopharma, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
AEON Biopharma, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
AEON Biopharma, Inc. reported a net loss of $39.2M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
AEON Biopharma, Inc.'s EBITDA was -$4.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
AEON Biopharma, Inc. reported $2.5M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
AEON Biopharma, Inc. held $11.4M in cash against $2.0M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
AEON Biopharma, Inc.'s quarterly ROE was 103.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
AEON Biopharma, Inc. invested $1.5M in research and development in Q3 2026. This represents an increase of 153.8% from the same quarter a year earlier. Against the prior quarter it is down 48.4%.
Not reported for Q3 2026.
Not reported for Q3 2026.
AEON Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.5M+153.8% | $2.9M+176.1% | $2.0M+146.5% | $1.6M-47.1% | $597K-38.6% | $1.1M-76.0% | $825K-85.6% | $3.0M |
| SG&A Expenses | $3.0M+54.7% | $3.0M-8.2% | $3.9M+24.9% | $3.9M+48.0% | $1.9M-36.5% | $3.3M-1.9% | $3.1M-32.8% | $2.6M |
| Operating Income | -$4.5Mn/m | -$5.9Mn/m | -$5.9Mn/m | -$5.5Mn/m | -$2.5Mn/m | -$4.3M-102.8% | -$462Kn/m | -$2.3M |
| EBITDA | -$4.5Mn/m | -$5.9Mn/m | -$5.9Mn/m | -$5.5Mn/m | -$2.5Mn/m | -$4.3M-102.8% | -$443Kn/m | -$2.3M |
| Net Income | $2.5Mn/m | -$1.2Mn/m | -$11.8M-229.7% | -$37.1M-1883.7% | -$4.5Mn/m | -$6.6M-104.0% | $9.1Mn/m | $2.1M |
| EPS (Basic) | $0.01 | -$0.02 | -$0.29 | -$3.72 | -$0.39 | -$0.60 | $2.28 | $3.21 |
| EPS (Diluted) | $0.01 | -$0.02 | -$0.29 | -$3.72 | -$0.39 | -$0.60 | $2.28 | $3.40 |
| Diluted Shares (Avg) | 90M | 51M | 41M | N/A | 12M | 11M | 4M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
AEON Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.1M+61.8% | $5.9M-49.3% | $8.6M-37.5% | $5.6M+77.0% | $8.7M+118.1% | $11.7M+103.4% | $13.8M+355.1% | $3.1M-54.1% |
| Current Assets | $12.6M+69.5% | $4.0M-61.1% | $6.6M-46.2% | $3.4M+113.7% | $7.4M+212.6% | $10.3M+155.3% | $12.3M+393.2% | $1.6M-74.4% |
| Cash & Equivalents | $11.4M+92.6% | $3.4M-59.3% | $6.2M-40.2% | $3.0M+23023.1% | $5.9M+1003.7% | $8.4M+145.2% | $10.4M+570.5% | $13K-99.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $11.7M-58.9% | $21.3M-22.7% | $25.4M+1.0% | $60.6M+91.1% | $28.6M-20.7% | $27.5M-18.3% | $25.1M-87.5% | $31.7M-80.2% |
| Current Liabilities | $4.6M-44.4% | $7.3M-19.6% | $6.7M-22.8% | $6.9M-51.3% | $8.2M-23.3% | $9.1M-12.5% | $8.6M-45.9% | $14.1M+8.4% |
| Non-Current Liabilities | $7.2M-64.8% | $13.9M-24.2% | $18.7M+13.5% | $53.7M+205.7% | $20.4M-19.7% | $18.4M-20.9% | $16.5M-91.1% | $17.6M-88.0% |
| Long-Term Debt | $2.0M-88.5% | $1.8M-88.4% | $1.5M-88.4% | $34.6M+196.0% | $17.1M+12.4% | $15.2M+14.2% | $13.3M+161.8% | $11.7M |
| Total Equity | $2.4Mn/m | -$15.4Mn/m | -$16.8Mn/m | -$55.0Mn/m | -$19.9Mn/m | -$15.9Mn/m | -$11.3Mn/m | -$28.6Mn/m |
| Retained Earnings | -$481.3Mn/m | -$483.8Mn/m | -$482.6Mn/m | -$470.8Mn/m | -$433.7Mn/m | -$429.1Mn/m | -$422.5Mn/m | -$431.6Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
AEON Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.7Mn/m | -$3.7Mn/m | -$2.6Mn/m | -$4.7Mn/m | -$2.6Mn/m | -$2.1Mn/m | -$7.9Mn/m | -$621Kn/m |
| Depreciation & Amortization | $15K-21.1% | $20K0.0% | $19K0.0% | $20K-13.0% | $19K-24.0% | $20K-16.7% | $19K-24.0% | $23K-4.2% |
| Stock-Based Compensation | $1.6M+60.0% | $1.9M+11.8% | $1.9M+11.7% | N/A | $1.0M-37.5% | $1.7M0.0% | $1.7M+6.7% | N/A |
| Capital Expenditures | N/A | N/A | N/A | $0 | $0 | $0 | $4K | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$4.7M | -$2.6M | -$2.1M | -$7.9M | N/A |
| Investing Cash Flow | N/A | N/A | N/A | $0 | $0 | $0 | -$4K | N/A |
| Financing Cash Flow | $13.7M+16239.3% | $886K+954.8% | $5.9M-68.0% | $1.8M+1746.4% | $84K+68.0% | $84K-99.2% | $18.3M+266.9% | $97K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AEON Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | 103.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 17.4%+69.4pp | -19.5%+37.4pp | -136.7%-202.6pp | -667.9%-734.2pp | -52.0%+102.2pp | -57.0%-2919.0pp | 65.9%+3958.3pp | 66.3% |
| Current Ratio | 2.75+1.8x | 0.54-0.6x | 0.99-0.4x | 0.49+0.4x | 0.90+0.7x | 1.12+0.7x | 1.43+1.3x | 0.11-0.4x |
| Debt-to-Equity | 0.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 4.92 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$55.0M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.49), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| AEON Biopharma, Inc. AEON | FY2025 | N/A | -$39.2M | N/A | $10.3M | — |
| Psyence Biomedical Ltd. PBM | FY2026 | N/A | -$6.9M | N/A | $11.3M | — |
| Quantum Biopharma Ltd. QNTM | FY2025 | N/A | N/A | N/A | $11.1M | — |
| Fractyl Health, Inc. GUTS | FY2025 | $0 | -$141.0M | N/A | $10.9M | — |
| TScan Therapeutics, Inc. TCRX | FY2025 | $10.3M | -$129.8M | N/A | $9.9M | 49/100 |
| Jasper Therapeutics, Inc. JSPR | FY2025 | N/A | -$75.8M | N/A | $9.6M | — |
Where AEON Biopharma, Inc. Ranks
Frequently Asked Questions
No, AEON Biopharma, Inc. (AEON) reported a net loss of $39.2M in fiscal year 2025.
AEON Biopharma, Inc. (AEON) had EBITDA of -$12.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, AEON Biopharma, Inc. (AEON) had $3.0M in cash and equivalents against $34.6M in long-term debt.
AEON Biopharma, Inc. (AEON) recorded an outflow of $17.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
AEON Biopharma, Inc. (AEON) recorded an outflow of $17.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
AEON Biopharma, Inc. (AEON) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.
AEON Biopharma, Inc. (AEON) invested $4K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
AEON Biopharma, Inc. (AEON) invested $4.1M in research and development during fiscal year 2025.
AEON Biopharma, Inc. (AEON) had a current ratio of 0.49 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
AEON Biopharma, Inc. (AEON) had a return on assets of -705.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
AEON Biopharma, Inc. (AEON) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $10.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
AEON Biopharma, Inc. (AEON) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $10.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, AEON Biopharma, Inc. (AEON) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.3M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
AEON Biopharma, Inc. (AEON) has negative shareholder equity of -$55.0M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
AEON Biopharma, Inc. (AEON) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
AEON Biopharma, Inc. (AEON) reported a net loss of $39.2M while operations used $17.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.